Melanotan (MT)-II 

Melanotan (MT)-II is a melanocortin receptor agonist. Melanotan (MT)-II activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction^[1][2][3][4].

Melanotan (MT)-II (20 μM, percutaneous immersion for 2 consecutive days) reverses high-fat diet-induced impairments in recognition memory, reduced exploratory behavior, and anxiety-like symptoms in zebrafish, restoring these indicators to levels comparable to those of animals fed a normal diet^[1].
Melanotan (MT)-II (2.5 μg per day; intracerebroventricular injection; continuous infusion; 7 days) rescues social ability deficits in adult male maternal immune activation (MIA) mice, increasing the social ability index score from 3.1 to 26.3^[2].
Melanotan (MT)-II (0.1-1 nM, microinjected bilaterally into the nucleus accumbens) significantly reduces 24-hour food intake in fasted C57BL/6J mice, produces a significant anorectic effect, and decreases feeding responses in ad libitum-fed mice^[3].
Melanotan (MT)-II (0.1-1 mg/kg, intravenous injection) significantly enhances the overall erectile activity in conscious rats and shortens the latency of the first erectile event in anesthetized rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1024.18

C₅₀H₆₉N₁₅O₉

121062-08-6

Solid

White to off-white

Ac-{Nle}-Asp-His-{d-Phe}-Arg-Trp-Lys-NH2, (2→7)-lactam

Ac-{Nle}-DH-{d-Phe}-RWK-NH2, (2→7)-lactam

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Wekwejt P, et al. Melanotan-II reverses memory impairment induced by a short-term HF diet. Biomed Pharmacother. 2023;165:115129.  [Content Brief]

  [2]. Minakova E, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019;14(1):e0210389. Published 2019 Jan 10.  [Content Brief]

  [3]. Eliason NL, et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289.  [Content Brief]

  [4]. Giuliano F, et al. The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats. Eur Urol. 2005 Jul;48(1):145-51; discussion 151-2.  [Content Brief]